Development of pharmaceutical grade cannabis drugs
CB21 Pharma aims to be a world leader in the development of cannabinoid therapeutics through evidence-based medicine, development processes and regulatory and manufacturing expertise. Maintaining our focus on the potential benefit to patients has been a consistent driving force in our research program and progress to date. By utilizing the most current science and technology, our R&D department consistently delivers the highest quality of novel-to-market end user products – cosmetics, dietary supplements, medical devices and medicines.
We value the expertise of the industry as a whole and welcome the opportunity for interesting collaborations with other companies.